# HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

> **NCT06335927** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 45 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** HAIC-GEMOX+Cadonilimab+Regorafenib

## Key facts

- **NCT ID:** NCT06335927
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-11
- **Primary completion:** 2025-05-10
- **Final completion:** 2026-05-10
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06335927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06335927, "HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06335927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*